Abstract: This disclosure relates to heterocyclic compounds of Formula (I), Formula (II), and Formula (III) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I), Formula (II), and Formula (III) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Formula (I), Formula (II), Formula (III).

Abstract: A compound of Formula I, which possesses 5-HT2A and/or 5-HT2C selective receptor activity, but lacks at lease some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.